# EDGAR Filing Document

**Accession Number:** 0001651625
**File Stem:** 0000950103-25-011258
**Filing Date:** 2025-9
**Character Count:** 10100
**Document Hash:** 81d4393eb20850660c3ff2cd412529af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-25-011258.hdr.sgml**: 20250904

**ACCESSION NUMBER**: 0000950103-25-011258

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250904

**FILED AS OF DATE**: 20250904

**DATE AS OF CHANGE**: 20250904

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AC Immune SA
- **CENTRAL INDEX KEY:** 0001651625
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37891
- **FILM NUMBER:** 251291859

**BUSINESS ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK, BUILDING B
- **CITY:** 1015 LAUSANNE
- **STATE:** V8
- **ZIP:** 00000
- **BUSINESS PHONE:** 41 21 345 91 21

**MAIL ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK, BUILDING B
- **CITY:** 1015 LAUSANNE
- **STATE:** V8
- **ZIP:** 00000

UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR<br> 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of September 2025

**Commission file number: 001-37891**

**AC IMMUNE SA**

(Exact Name of Registrant as Specified in Its Charter)

**EPFL Innovation Park<br> Building B<br> 1015 Lausanne, Switzerland**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or<br> Form 40-F.

Form 20-F ☒ Form 40-F ☐

On September 4, 2025, AC Immune SA ("**AC Immune**") issued a press release reporting that, following a strategic review by executive management, AC Immune is sharpening its focused investment on its most important assets. These include its three clinical-stage active immunotherapy programs, two of which are in ongoing pharma collaborations, and its most promising small molecule programs targeting NLRP3 and Tau. As a result, AC Immune will reduce its workforce by around 30% and extend its cash for operations to the end of the third quarter of 2027.

A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K.

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **AC IMMUNE SA** | **AC IMMUNE SA** | **AC IMMUNE SA** |
| By: | /s/ Andrea Pfeifer | /s/ Andrea Pfeifer |
|  | Name: | Andrea Pfeifer |
|  | Title: | Chief Executive Officer |
| By: | /s/ Christopher Roberts | /s/ Christopher Roberts |
|  | Name: | Christopher Roberts |
|  | Title: | Chief Financial Officer |

---

Date: September 4, 2025

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| [99.1](dp233965_ex9901.htm) | [Press release dated September 4, 2025](dp233965_ex9901.htm) |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](image_001.jpg) | **PRESS RELEASE** |

---

**AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Strategic review by executive management yields increased pipeline focus and
operational efficiencies with a workforce reduction of around 30%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Increased emphasis on late-stage clinical development of active immunotherapy
portfolio for Alzheimer's and Parkinson's diseases and progressing high value candidates enabling intracellular targeting

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Near term clinical milestones remain unchanged

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Cash resources of CHF 127.1 million as of June 30, 2025, now provides cash
for operations to the end of Q3 2027 not including potential payments from partnering

**Lausanne, Switzerland, September 4th, 2025 --** AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that following a strategic review by executive management, the Company is sharpening its focused investment on its most important assets. These include its three clinical-stage active immunotherapy programs, two of which are in ongoing pharma collaborations, and its most promising small molecule programs targeting NLRP3 and Tau. As a result, the Company will reduce its workforce by around 30% and extend its cash for operations to the end of Q3 2027.

**Dr. Andrea Pfeifer, CEO of AC Immune SA, commented:** "We are making meaningful progress with our product candidates to treat and prevent neurodegenerative diseases and are eagerly approaching multiple potentially transformational milestones over the next two years. This is true both in our ongoing collaborations with Janssen, Takeda and Lilly, and in our wholly-owned programs where progress will further strengthen opportunities for more partnering.

The actions we are taking now extend our cash runway to the end of Q3 2027, excluding anticipated business development milestone payments from existing or potential new business deals. It has been a challenging and carefully considered decision and I want to recognize all our colleagues whose professionalism, expertise and passion have resulted in many invaluable contributions to our mission over the years.

Going forward, we will focus our resources on our Phase 2 active immunotherapies and the development of our most exciting novel therapeutics targeting intracellular mechanisms of neurodegenerative diseases, including NLRP3 and Tau."

AC Immune maintains its guidance on previously announced timelines with interim clinical data from both ACI-7104.056 and ACI-24.060 expected in H2 2025 and H1 2026, respectively.

In accordance with Swiss employment law a consultation process with employees has been initiated. Upon completion of the consultation process, the Company will offer affected employees support. This will include, but will not be limited to, severance packages, and support in seeking new employment,

coaching or training opportunities. AC Immune foresees the full implementation of these changes enacted by the end of 2025 and the reduction of costs to become fully effective early in 2026.

**About AC Immune SA** 

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen<sup>®</sup> and Morphomer<sup>®</sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

SupraAntigen<sup>®</sup> is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer<sup>®</sup> is a registered trademark of AC Immune SA in CN, CH, EU, GB, JP, KR, NO, RU and SG.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

**For further information, please contact:**

---

| |
|:---|
| **SVP, Investor Relations & Corporate Communications<br>** <br> Gary Waanders, Ph.D., MBA<br> AC Immune<br> Phone: +41 21 345 91 91<br> Email: <u>gary.waanders@acimmune.com</u> |
| **International Media<br>** <br> Chris Maggos<br> Cohesion Bureau<br> Phone: +41 79 367 6254<br> Email: <u>aciu@cohesionbureau.com</u> |

---

**Forward looking statements**

This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them

in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.